Alumis Inc. Common Stock (ALMS) News
Latest headlines that mention ALMS, newest first · each headline opens the original publisher
- Last price
- $6.51
- Day change
- -3.98%
- Next earnings
- 2026-11-12
ALMS headlines
latest coverageAlumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
ALMS news alerts
Get an alert by email or push when a new headline mentions ALMS.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.